Fig. 3

The performance of OncoUrine in recurrence prediction during follow-up. A The clinical and OncoUrine results of the recurred patients during follow-up. The correlation of recurrence during follow-up with test and clinical results was shown in B and D, respectively. C The lead time of recurrence between OncoUrine test results and clinical confirmed recurrence. The term “OncoUrine recurrence” refers to a positive test result at recruitment while “Clinical recurrence” refers to the tumor recurrence subsequently confirmed by cystoscopy and pathology. The x axis indicates the time since TURBT. The recurrence free survival plot showed that a negative OncoUrine test was associated with a better outcome (E) and adding OncoUrine result to clinical diagnosis could further stratify patients’ risk (F). Statistical significance was calculated by log-rank tests. LG, low grade. HG, high grade. MIBC, muscle invasive bladder cancer. OncoUrine + , OncoUrine positive. OncoUrine -, OncoUrine negative. Clinical + , clinical positive. Clinical -, clinical negative